These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1729540)

  • 1. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.
    Spencer WF; Linehan WM; Walther MM; Haas GP; Lotze MT; Topalian SL; Yang JC; Merino MJ; Lange JR; Pockaj BA
    J Urol; 1992 Jan; 147(1):24-30. PubMed ID: 1729540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
    Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
    J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ.
    Bex A; Horenblas S; Meinhardt W; Verra N; de Gast GC
    Eur Urol; 2002 Dec; 42(6):570-4; discussion 575-6. PubMed ID: 12477652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
    Giacosa R; Santi R; Vaglio A; Pavone L; Ferrozzi F; Passalacqua R; Buzio C
    Acta Biomed; 2004 Aug; 75(2):126-30. PubMed ID: 15481703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive nephrectomy in metastatic renal cancer.
    Flanigan RC
    Curr Urol Rep; 2003 Feb; 4(1):36-40. PubMed ID: 12537937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
    Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
    Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
    Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
    Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission of extensive metastatic renal cancer following immunotherapy.
    Plowman PN; Costello J; O'Donoghue N
    Clin Oncol (R Coll Radiol); 1997; 9(3):176-80. PubMed ID: 9269551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ.
    Shinohara N; Abe T; Sazawa A; Maruyama S; Shindo J; Sato S; Suzuki S; Nonomura K
    Jpn J Clin Oncol; 2012 Feb; 42(2):113-9. PubMed ID: 22131341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy in the management of metastatic renal carcinoma].
    Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
    Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.
    Walther MM; Alexander RB; Weiss GH; Venzon D; Berman A; Pass HI; Linehan WM; Rosenberg SA
    Urology; 1993 Sep; 42(3):250-7; discussion 257-8. PubMed ID: 8379024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.
    Fallick ML; McDermott DF; LaRock D; Long JP; Atkins MB
    J Urol; 1997 Nov; 158(5):1691-5. PubMed ID: 9334580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
    Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
    Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
    Fleischmann JD; Kim B
    J Urol; 1991 May; 145(5):938-41. PubMed ID: 2016805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferons and interleukins in metastatic renal cell carcinoma.
    Choudhury M; Efros M; Mittelman A
    Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.